Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.47 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.47 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808999 | 0.90 | AKR1C1 (0.75) | AKR1C1KMT2AHSD11B1HDAC1 | |
| SCHEMBL31016196 | 0.87 | AKR1C1 (0.83) | AKR1C1CYP2C19KMT2ATET3FBXL19 | |
| SCHEMBL6391 | 0.87 | AKR1C1 (0.83) | AKR1C1CYP2C19KMT2ATET3FBXL19 | |
| Hydrochloric Acid SCHEMBL3866423 | 0.85 | AKR1C1 (0.79) | AKR1C1CYP2C19KMT2ATET3FBXL19 | |
| SCHEMBL30662077 | 0.84 | AKR1C1 (0.46) | AKR1C1HSD11B1HDAC1 | |
| SCHEMBL15912397 | 0.84 | CYP2C19 (0.50) | AKR1C1APPCYP2C19CYP2C9CYP2D6 | |
| SCHEMBL9939471 | 0.81 | AKR1C1 (0.47) | AKR1C1APPCYP2C19CYP2C9CYP2D6 | |
| SCHEMBL11665752 | 0.81 | AKR1C1 (0.88) | AKR1C1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL19881196 | 0.81 | PRKAB2 (0.52) | AKR1C1APPCYP2C19CYP2C9CYP2D6 | |
| SCHEMBL27851854 | 0.80 | MAPT (0.50) | AKR1C1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100475813-C | 4-oxo-1- (3-substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2009-04-08 | — | — | CN | claimed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | claimed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| CN-1738819-A | 4-oxo-1- (3-substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2006-02-22 | — | — | CN | claimed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | claimed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | claimed |
| EP-2648726-B1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9556133-B2 | Polycyclic LPA1 antagonist and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| CN-103596566-A | Polycyclic LPA1 antagonists and uses thereof | AMIRA PHARMACEUTICALS INC | 2014-02-19 | — | — | CN | disclosed |
| EP-2438048-B1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2648726-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| CN-100475813-C | 4-oxo-1- (3-substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2009-04-08 | — | — | CN | disclosed |
| EP-1824858-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | Aventis Pharma S.A. (FR) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061258-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| CN-1738819-A | 4-oxo-1- (3-substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2006-02-22 | — | — | CN | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-3947588-A | Cyclopropane carboxylic acid derivatives for lowering the level of ketone bodies | SCHERING CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | LPAR1, LPAR2, LPAR4 | AKR1C1 1523/4885APP 3084/4885CYP2C19 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.